Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

ticagrelor (TA236, 2011). For a short explanation of why the committee made the 2020 recommendation and how it might affect practice, see the rationale and impact section on dual antiplatelet therapy for people with unstable angina or NSTEMI. Full details of the evidence and the committee's discussion are in evidence review A: antiplatelet therapy. 1.2.18 If stenting is indicated, offer a drug-eluting stent to people with unstable angina or NSTEMI undergoing revascularisation by PCI. [2020] Acute coronary syndromes (NG185) For a short explanation of why the committee made the 2020 recommendation and how it might affect practice, see the rationale and impact section on drug-eluting stents. Full details of the evidence and the committee's discussion are in evidence review F: drug-eluting stents. Glycoprotein IIb/IIIa inhibitors for complex PCI 1.2.19 Glycoprotein IIb/IIIa inhibitors as an adjunct to PCI are recommended as an option in NICE technology appraisal guidance for people with unstable angina or NSTEMI who are having complex procedures. For full details, see the guidance on glycoprotein IIb/IIIa inhibitors (TA47, 2010). Management when PCI is not indicated 1.2.20 Consider conservative management without early coronary angiography for people with unstable angina or NSTEMI who have a low risk of adverse cardiovascular
